<DOC>
	<DOC>NCT01066884</DOC>
	<brief_summary>This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patients &gt;= 18 years of age; inoperable, locally advanced, recurrent or metastatic (Stage IIIB/IV) nonsmall cell lung cancer; ECOG performance status of 03; previously untreated, or failed on one prior course of standard systemic chemotherapy and/or radiotherapy. prior systemic antitumor therapy with HER1/EGFR inhibitors; unstable systemic disease; any other malignancies within 5 years (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer; any significant ophthalmologic abnormality.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>